Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma
Chihiro Fushimi, Isaku Okamoto, Takashi Matsuki, Tatsuo Masubuchi, Takuro Okada, Hiroki Sato, Kiyoaki Tsukahara, Takahito Kondo, Taku Yamashita, Kenji Hanyu, Go Omura, Hideaki Takahashi, Yuichiro Tada, Kouki Miura
Abstract
BACKGROUND/AIM: The treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has remained challenging. The effect of salvage chemotherapy (SCT) after nivolumab has been identified recently in other cancer types. The aim of this study was to examine the efficacy of SCT after nivolumab treatment in patients with R/M HNSCC. PATIENTS AND METHODS: A retrospective study was conducted at four institutions in Japan. Fifty-six patients were enrolled in the study. RESULTS: The overall survival (OS) in SCT patients was significantly longer than that in best supportive care (BSC) patients. In the SCT patients, the median OS, median progression-free survival (PFS) and objective response rate (ORR) were 7.3 months, 2.3 months and 36%, respectively. Prognostic factor for OS and ORR was performance score (PS) and previous radiation, respectively. CONCLUSION: SCT after nivolumab is associated with better clinical outcomes in patients with R/M HNSCC compared to those receiving BSC.